UNIVERSITÄT AUGSBURG
Universitätsbibliothek

OPEN ACCESS
OPUS AUGSBURG

Test-retest reproducibility of radiomic features on PSMA-targeted F-18-DCFPyL PET/CT in patients with metastatic prostate cancer [Abstract]

Rudolf Werner, Bilel Habacha, Lena Bundschuh, Takahiro Higuchi, Sebastian Serfling, Thorsten Derlin, Markus Essler, Constantin Lapa, Kenneth Pienta, Andreas Buck, Mario Eisenberger, Mark Markowski, Martin Lodge, Martin Pomper, Michael Gorin, Steven Rowe, Ralph Bundschuh

Angaben zur Veröffentlichung / Publication details:

Werner, Rudolf, Bilel Habacha, Lena Bundschuh, Takahiro Higuchi, Sebastian Serfling, Thorsten Derlin, Markus Essler, et al. 2021. "Test-retest reproducibility of radiomic features on PSMA-targeted F-18-DCFPyL PET/CT in patients with metastatic prostate cancer [Abstract]." *Journal of Nuclear Medicine* 62 (Suppl. 1): 1353.
https://jnm.snmjournals.org/content/62/supplement_1/1353.

Nutzungsbedingungen / Terms of use:

licgercopyright

Dieses Dokument wird unter folgenden Bedingungen zur Verfügung gestellt: / This document is made available under these conditions:
Deutsches Urheberrecht
Weitere Informationen finden Sie unter: / For more information see:
https://www.uni-augsburg.de/de/organisation/bibliothek/publizieren-zitieren-archivieren/publiz/

Test-Retest Reproducibility of Radiomic Features on PSMA-targeted ^{18}F-DCFPyL PET/CT in Patients with Metastatic Prostate Cancer

Rudolf Werner, Bilel Habacha, Lena Bundschuh, Takahiro Higuchi, Sebastian Serfling, Thorsten Derlin, Markus Essler, Constantin Lapa, Kenneth Pienta, Andreas Buck, Mario Eisenberger, Mark Markowski, Martin Lodge, Martin Pomper, Michael Gorin, Steven Rowe and Ralph Bundschuh

Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1353;

Abstract

1353

Objectives: Prostate-specific membrane antigen (PSMA)-targeted imaging has emerged as a powerful clinical tool to detect prostate cancer (PC). Beyond conventional PET parameters, extracted mathematically quantitative features (radiomic metrics) have gained increasing interest in recent years. We aimed to evaluate 18F-DCFPyL test-retest reproducibility of radiomic features in widespread disease.

Methods: In a prospective clinical trial (NCT03793543), 23 patients with histologically proven PC underwent two 18F-DCFPyL PET scans within 7 days (mean 3.7, range 1 to 7d). Lesions in bone, lymph nodes and other organs were manually segmented on both scans and radiomic feature metrics were assessed (in total 31, including first-order parameters [e.g. kurtosis], second-order parameters [e.g. entropy, homogeneity] and higher-order parameters [e.g. busyness, coarseness, complexity, contrast, long zone emphasis]). Repeatability of quantification was determined using correlations and within- subject coefficient of variation (wCOV, in percentage; <10% indicating excellent, 10-20% good, 20-30% acceptable and >30% unacceptable reproducibility).

Results: In total, 230 lesions (177 bone, 38 lymph nodes, 15 others) were delineated in both scans. For all investigated radiomic features, a broad range of inter-scan correlation was found (R2, entropy, 0.96 to long zone emphasis, 0.09). Analyzing all lesions, the wCOVs for entropy and homogeneity were 16.0% and 12.7%, respectively, indicating good reproducibility for second-order radiomic features. The wCOV of these radiomic features derived from LN and bone metastases, however, did not show any significant differences (wCOV entropy: LN, 16.4 % vs. skeleton, 14.9 %, P=0.42; wCOV homogeneity: LN, 14.2 % vs. skeleton, 12.4 %, P=0.26). First-order parameters (kurtosis, wCOV, 8452%) and third-order parameters (wCOV: busyness, 21.7%; contrast, 90.8%; complexity, 144.9%; coarseness, 162.1% or long zone emphasis, 630.4%) demonstrated acceptable to unacceptable reproducibility.

Conclusions: Second-order parameters entropy and homogeneity demonstrated good reproducibility on 18F-DCFPyL PET with no significant difference in performance between lymphatic or osseous tumor burden, suggesting stability of these radiomic features even among different organ compartments. Second-order parameters may be the subject of future studies or clinical trials, while other radiomic metrics may not add additional information in the setting of PSMA-directed imaging.